newsfilter
← Latest News
GlobeNewswire·

TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine

National Institute of Health/National Institute of Allergy and Infectious Disease Direct to Phase II SBIR Grant Will Fund Preclinical and IND Enabling Studies on a Shelf-Stable Mucosal Delivered Universal Flu Vaccine